Additional phase 2 data comes from a 26-week, open-label study in insulin-naivepatients with T2D, in which 278 patients were randomly assigned to 1:1 to efsitoraonce-weekly or IDeg once-daily (129). The gene discussed is INS; the disease is type 2 diabetes mellitus.